C-DQ79Lift Biosciences
allogeneic neutrophils, cell therapy, immuno-oncology
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-DQ79
C-DQ79C-DQ79allogeneic neutrophils, cell therapy, immuno-oncology
0-100 chain-logic scale · 15 dimensions · scored on public evidence
LIfT's Chairman on innate immune rejuvenation for cancer | LIFT BioSciences posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, … immunotherapy and explore the role of #Tregs , the focus of this year’s #Nobel Prize in Medicine or Physiology. View Editor-in-Chief Dr. Michael Lotze’s top #IO research picks: https://lnkd.in/g7uN2RQj 5 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in University of Notre Dame 242,797 followers 8mo Report this post For those battling glioblastoma, every moment matters. This aggressive brain cancer grows fast, adapts quickly, and leaves patients a … r add a comment, sign in Alireza Bahramirad 8mo Report this post The 2025 Nobel Prize in Medicine: The Treg Cell Discovery The Nobel Prize in Physiology or Medicine was awarded to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their paradigm-shifting discoveries in immune regulation. By combining keen observation with rigorous experiments, they identified and characterized the crucial CD4+CD25+FOXP3+ regulatory T cells (Treg cells). Their work demonstrated the essen
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
--> LIfT BioSciences appoints Antonin (Tony) de Fougerolles as Chairman of its Board of Directors top of page Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. All Posts Search LIfT BioSciences appoints Antonin (Tony) de Fougerolles as Chairman of its Board of Directors Jul 1, 2024 2 min read Updated: Apr 11, 2025 London, 1 July 2024– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company preparing to start clinical trials for its first-in-class allogeneic innate
--> LIfT BioSciences announces breakthrough preclinical data demonstrating dual mode of action top of page Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. All Posts Search LIfT BioSciences announces breakthrough preclinical data demonstrating dual mode of action Mar 21, 2023 3 min read Updated: Apr 11, 2025 LIfT BioSciences announces breakthrough preclinical data demonstrating the dual mode of action commonly believed necessary for curing solid tumours - IMANp is the world’s first neut
LIfT BioSciences announces partnership with University of Galway for clinical trial in Ireland | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
LIfT BioSciences Appoints World-Leading Cancer Immunotherapy Experts to Scientific Advisory Board Ahead of First-in-Human IMAN Trials 26 June, 2026 | Friday Home Editorial 2026 Media Pack BioPharma Exclusive Subscribe Events Login BioPharma USFDA Drug Development Pharma Research Regulatory Clinical Trial Pharma Manufacturing Product Development and Pipeline Genomic and Personalized Medicine LifeSciences Biotech Biologics Clinical & Diagnostic Rare Diseases Therapeutics Lab Lab Products Lab Testing Contract Pharma Contract Research Contract Manufacturing Healthcare Digital Health Bio Innova … and cervical cancer. The consortium led by LIfT is funded by a €12 million grant awarded by Ireland’s Disruptive Technologies Innovation Fund (DTIF). The Company has also successfully completed a Scientific Advice meeting with the Irish regulatory agency, HPRA. The agency's feedback allows LIfT to finalise its overall manufacturing strategy and design of its clinical study to be conducted in Ireland. “The participation from such an esteemed group of experts f … ed immune checkpoint inhibitor. For this work, he was co-awarded the 2018 Nobel Prize in Physiology or Medicine. Dr. Allison is Regental Professor and Chair of the Department of Immunology, the Olga Keith Wiess Distinguished University Chair for Cancer Research, Executive Director of the Immunotherapy Platform, and Director of the James P. Allison Institute at The University of Texas MD Anderson Cancer Center. Dr. Allison’s current research focuses on next-generation im … ancers. Her work has been recognised with awards including the William B. Coley Award in Tumor Immunology and the Emil Frei III Award for Excellence in Translational Research. Dr. Sharma is Associate Vice President of Immunobiology and Professor of Genitourinary Medical Oncology and Immunology, and Director of Scientific Programmes for the James P. Allison Institute at The University of Texas MD Anderson Cancer Center. She holds an MD and a PhD from Pennsylvania State Univers … une-based cancer therapies and bridging fundamental immunobiology with clinical application. This work has advanced multiple immunotherapy strategies through highly collaborative efforts across leading academic, clinical and industry partners. Dr. Merghoub is Deputy Director of the Meyer Cancer Center, Margaret and Herman Sokol Professor of
LIfT BioSciences Appoints Mark A. Exley as Chief Scientific --> Accessibility: Skip TopNav LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer April 07, 2025 02:00 ET | Source: LIfT BioSciences LIfT BioSciences Mark brings 30 years of experience in R&D spanning discovery to late-stage clinical development London, 7 April 2025 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and world leader in neutrophil immuno-therapies, today announces the appointment of Mark A. Exley, PhD as Chief Scientific Officer (CSO), effective 7 April. The appointmen
London-based LIfT BioSciences secures €12 million to ovecome treatment resistance in solid tumours | EU-Startups | EU-Startups LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to … es , a British BioTech focused on neutrophil immunotherapies, today announces a grant of €12 million has been awarded from Ireland’s Disruptive Technologies Innovation Fund (DTIF) 🇬🇧/🇮🇪 🦠 The €12 million grant, the largest grant awarded by the DTIF to date, was awarded to a consortium LIfT formed with the University of Galway , known for their expertise in cell therapy development, innovation, and clinical trials; and Hooke Bio Ltd. , innovators of a novel immuno-analyti … s platform designed to enhance therapy response rates, as part of the Company’s grant application process. Alex Blyth , Chief Executive Officer of LIfT Biosciences, said: “The grant awarded from DTIF is a significant milestone for LIfT as we expand our presence in Ireland and advance toward closing the second round of our Series A financing. By combining LIfT’s innovative immunotherapy platform with the University of Galway’s deep expertise in oncology, patient care, and adva … Prevention and Research Institute of Texas—part of a $17.6 million non-dilutive grant powering its radiotherapeutic program for leptomeningeal metastases. That may sound routine, but it signals a deeper shift in how early-stage biotech is surviving the current funding climate: stacking grant capital to advance high-cost, high-impact platforms while preserving equity. What makes Plus’ strategy interesting isn’t just the money—it’s the model. The company is developing REYOBIQ, … ship funding to advance innovation where private markets hesitate. Do you think grant-backed innovation can sustain momentum in high-cost therapeutic areas—or does scale inevitably require big pharma partnerships? 𝐑𝐞𝐚𝐝 𝐌𝐨𝐫𝐞: https://lnkd.in/d9W7WnUh #Radiopharma #OncologyInnovation #BiotechStrategy #MedicalAffairs #MarketAccess Marc Hedri
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JLABS - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JLABS December 19, 2022 | 3 min read Twitter LinkedIn Facebook Email Print LIfT BioSciences is pleased to announce that it’s lead investor, Starbloom Capital, has provided further investment into the Company to accelerate L … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
LIfT BioSciences appoints Antonin (Tony) de Fougerolles as Chairman of its Board of Directors | GlobeNewswire by notified Hjem Følg innhold Våre kunder Om tjenesten Bli kunde LIfT BioSciences appoints Antonin (Tony) de Fougerolles as Chairman of its Board of Directors 1.7.2024 08:00:00 CEST | GlobeNewswire by notified | Press release Share LIfT BioSciences appoints Antonin (Tony) de Fougerolles as Chairman of its Board of Directors London, 1 July 2024– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company preparing to start clinical trials for its first-in-class allog
--> LIfT BioSciences announces partnership with University of Galway for clinical trial in Ireland top of page Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. All Posts Search LIfT BioSciences announces partnership with University of Galway for clinical trial in Ireland Apr 28, 2025 3 min read Updated: Aug 4, 2025 London , 28 April 2025 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces progress
--> LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JL top of page Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. All Posts Search LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JL Dec 19, 2022 3 min read Updated: Apr 11, 2025 London, 19 December 2022 – LIfT BioSciences is pleased to announce that it’s lead investor, Starbloom Capital, has provided further investment into the Company
Great to be part the LifT team and this important mission of changing the lives for patients. I’m pleased to join LIfT at this pivotal time, as we look to move our allogeneic first-in-class… | Bo Rode Hansen LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any tim
Press Release Distribution and Management Accessibility: Skip TopNav Latest News and Press Releases Want to stay updated on the latest news? Sign into Reader Account Create Reader Account May 07, 2026 06:00 ET | Source: LIfT BioSciences LIfT Biosciences Establishes Scientific Advisory Board to Accelerate Development of Neutrophil-based Cancer Therapies Members include Nobel laureate James P. Allison, Padmanee Sharma, Taha Merghoub, and Kingston Mills, who are all globally renowned experts in cancer immunotherapy and translational cancer... April 22, 2026 09:30 ET | Source: LIfT BioScien … .. July 29, 2025 02:00 ET | Source: LIfT BioSciences LIfT BioSciences announces grant of €12 million from Ireland’s Disruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy Galway, London, 29 July 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces a grant of €12 million... June 25, 2025 02:00 ET | Source: LIfT BioSciences LIfT BioS
Why Partner - 11th Innate Killer Summit Skip to content This event has run. Thank you to our speakers, sponsors, and delegates who joined us for the 2026 summit. Returning March 2027 About About Event FAQs Interview with Nina Horowitz Hanson Wade Products What’s On? Full Event Guide Speakers Why Partner Why Partner Partners Media Partners Take Part Register Interest Contact Us Previous Event Guide Register Interest About About Event FAQs Interview with Nina Horowitz Hanson Wade Products What’s On? Full Event Guide Speakers Why Partner Why Partner Partners Media Partners Take Part R
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
LIfT BioSciences | BIO-Europe You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. November 9–11, 2026 Koelnmesse Cologne, Germany Home home Ways to attend expand_more Registration Options Company Presentation Options Delegations Program expand_more 2026 Agenda Ag
LIfT BioSciences receives €12m grant for cancer therapy trials | bionity.com posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, yo … tent People Learning Jobs Games Join now Sign in LIfT BioSciences receives €12m grant for cancer therapy trials bionity.com 2,884 followers 10mo Report this post €𝟭𝟮𝗠 𝗳𝗼𝗿 𝗟𝗜𝗳𝗧 𝗕𝗶𝗼𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀: 𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗶𝗻 𝗖𝗮𝗻𝗰𝗲𝗿 𝗧𝗵𝗲𝗿𝗮𝗽𝘆?: LIfT BioSciences a rapidly emerging biotech and the global leader in neutrophil immunotherapies, announces a grant of €12 million has been awarded from Ireland’s Disruptive Technologies Innovation Fund (DTIF) t … gh first-in-human clinical trials expected to start in Q4 2026. The €12 million grant, the largest grant awarded by the DTIF to date, was awarded to a consortium LIfT formed with the University of Galway , renowned for their expertise in cell therapy development, innovation, and clinical trials and Hooke Bio, pioneers of a novel immuno-analytics platform designed to enhance therapy response rates, as part of the Company’s grant application process. The funding will be used to … lebrate Dr. LaBarbera and his team for securing a $2.5M NIH–NCI Fast-Track STTR grant, and to support their journey with partners like Fitzsimons Innovation Community and InnoSphere Ventures . #CUInnovations #CancerResearch #HealthcareInnovation University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences 30 3 Comments Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in EigerTech Knowledge Services 879 followers 8mo Report this post � … ), four Established Investigator Awards (EIA) and the MRFBC Pilot Translational Award. These grants will support groundbreaking projects in earlier diagnosis of lethal melanoma, innovative therapies for acral and mucosal melanoma, new strategies to overcome drug resistance and more. Through the MRF’s Research & Science Grant Program, more tha
Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual Meeting Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management Brexit Sport Premier League Football Formula 1 Rugby Cricket Golf … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets closed UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets closed FTSE 100 10,529.89 +68.26 +0.65% GBP/USD 1.3194 +0.0030 +0.23% GBP/EUR 1.1598 +0.0008 +0.07% FTSE 250 23,161.41 +59.89 +0.26% AIM 771.92 -5.45 -0.70% GOLD FUTURES 4,044.60 -3.00 -0.07% ADVERTISE
--> LIfT at The Rejuvenation Summit top of page Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. All Posts Search LIfT at The Rejuvenation Summit Oct 21, 2022 1 min read Updated: Apr 11, 2025 LIfT BioSciences presented at Forever Healthy Foundation's Rejuvenation Summit In Berlin. Alex Blyth, LIfT's CEO, presented on the links between cancer cells and senescent cells, and how both can be treated with their N-LIfT cell therapy platform. The N-LIfT Platform allows LIfT to produc
--> Investor Information | Lift Biosciences Cancer Cell Therapy top of page Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. LIFT BioSciences is supported by successful investors known for their track record in promoting transformative companies. We have secured over £17 million in funding and have been awarded, as part of a consortium, a €12 million DTIF grant from Enterprise Ireland. We are actively seeking additional investors and collaborators to further progress our nove
--> Career | LIfT BioSciences top of page Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. RECRUITMENT Are you someone who wants to use their specialised skills to help h uman ity and fight our battle agains t cancer? Applicants must have a passion for curing cancer and recognise the need to do things differently. [email protected] LIfT Biosciences vision is to develop the world’s first cell bank of mass produced ‘cancer killing neutrophils’ to del
LIfT BioSciences hails breakthrough for curing solid tumors Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Sectors Browse by
%PDF-1.4 %���� 928 0 obj > endobj xref 928 121 0000000016 00000 n 0000004944 00000 n 0000005106 00000 n 0000008140 00000 n 0000008254 00000 n 0000009790 00000 n 0000010048 00000 n 0000010300 00000 n 0000010743 00000 n 0000011230 00000 n 0000011825 00000 n 0000011937 00000 n 0000012433 00000 n 0000012902 00000 n 0000013034 00000 n 0000013062 00000 n 0000013089 00000 n 0000013648 00000 n 0000014091 00000 n 0000014659 00000 n 0000014798 00000 n 0000015099 00000 n 0000015368 00000 n 0000015752 00000 n 0000016141 00000 n 0000016418 00000 n 0000016502 00000 n 0000016823 00000 n 0000043620 00000 n 00 … 24-07-17T13:03:20+05:30 2024-07-17T13:03:20+05:30 Adobe InDesign 19.5 (Windows) application/pdf uuid:648069ef-cfa4-4fc6-9fae-e6be97dd1bfc uuid:ff2982ea-7bf2-4f2b-a302-bbbf5928b9c4 Adobe PDF Library 17.0 endstream endobj 1012 0 obj > endobj 1013 0 obj > endobj 1014 0 obj > endobj 1015 0 obj >/Shading >>>/Subtype/Form>>stream H�*�2PH��wR�\F�fz&���&f �&��z���ƦF�h de��z�ff�Ɔf f�@E&ff ɹ\N �� � � �\��� endstream endobj 1016 0 obj > endobj 1017 0 obj > endobj 1018 0 o … �Z���e���j�Z�>߁Se]Pn�Sl�Q`��o�m��*"�04� ,�(2�4:{u|�Uj�͕"k6Ǧ�g_�����V,�l��˥��RFP��Tr���[4�����X%7[��e��@�fU���� @٪��T�0Q��xIxU���M��BнY}��B���+�[֊��%V�:�b�U^��� ����B��U٫�.�^1 �b �K�a��/�I)u�����-J�l*��V�� ekdm�-j�6�����n�l_�� �4�۩:�:o�N������[x�6���ē��/ =��홧��9~� �}��}����RO �Sܶ��XN���pF�팺;i�×j���M�����7ѫ � �� ��λ�o1�;X��a�ZVQ7��;�ӛ����D�nQ�����(|3�] J �Xw(��@L��X�������O��?�n��S�h�o�)� .�K{ȥ=Բ JY �����R����Z*����2�z� �� �B� � FT�*X��� … m�7�Ű8k��@a��5�-��Δ[,� ;d�\����� ����NSL7�Z�]$��Z�P;�7o��u�-h����lfOa��rFp�gL�.�_���#�����`0h�r��.��ɠ�c~x�h��yP �J��Ğ��o9����R1� ���`���/9'�B -\��|>��2 N~�'c�&�q �� 6����I�]�T6`�^mF�)Z�V;z����'ign�� �/y�t�k?d�!:�r,;WU&��7:xY�y"�Rq6H �s�̅���F�6����g���ƈ�����F�=����mI �� 9E�i*�b|S���)O�X��(Qg��0��2-���W]9uªg��ᰝ�///|o�S���|� E�N���h�MIOAE���- s�ۿ�H�r���w)X7�����(�k������E{m����ǏFi"���{r�|�S�(O��� ٷvY����3��֓z�z�#�� EbA�_�K�l�(�p����L���m�s��s �Q �# … �pB,��.�ʡ~x�B�E?M("�ZQ��5r|�BCћϓ)��ܪ\`lW�\�_�]i��qPD�` S�O~=���-e��� �{��ݹRfP��hX� ,es�3s�� *��=��V93x7�O}��3w�?[� �� Y���7\�֓��3kOׂ�i���i���Ṯ~���Ӈ��w ��sH�����ǿ�'??����_��O��/���������Z~�Z&� �;O �ɛ���6��W�W�W�U~}�2[��X��� �3 ���ş~��W�a6���{�n�������j�x9;��z*�!��6�� m�U��l.w�ܑc� e��p�5� s��; �5vIo���w�8W� ų- GHSpB�%
--> LIfT BioSciences Secures Another Landmark US Patent, Strengthening Its Position as the World Leader in Neutrophil Immunotherapies top of page Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. All Posts Search LIfT BioSciences Secures Another Landmark US Patent, Strengthening Its Position as the World Leader in Neutrophil Immunotherapies Mar 13, 2025 2 min read Updated: Apr 11, 2025 London, 13 March 2025 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the
Radiation Oncology Advances with Dr Damola Omogbehin | Misbah O. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to L
Alex Blyth's Journey of Reimagining The Limits of Human Health Spanned By Enhancing Your Immune IQ Skip to main content Starting Up News Technology Franchises Sign in My Account Submit Article Sign Out Edition United States Spanish Georgia India Asia Pacific Middle East United Kingdom Europe Search Search My Account Submit Article Sign Out Starting Up News Technology Franchises Sign in My Account Submit Article Sign Out LLC Formation Start now Starting Up News Technology Franchises / Entrepreneurs Alex Blyth’s Journey of Reimagining The Limits of Human Health Spanned By Enhancing Yo … ommitment, including the decision to sell his own properties and businesses, to fund his initial research. Gradually, he observed recurring themes suggesting that immune effectiveness shifts over time, shaped by both genetic and environmental influences. These insights informed his decision to found LIfT Biosciences, where he focused on developing a new approach to cell therapy. Building on the idea that certain innate immune responses may offer useful advantages, he explored
Bio-Techne Advanced Therapies 2024 Log in Language Resource center Contact app support Legal Home Agenda Speakers Bio-Techne Gold Sponsor 34 Bookmark Sessions Information Bio-Techne is a global developer, manufacturer and supplier of high-quality reagents, analytical instruments, and precision diagnostics. Whether you’re at the cutting edge of academic research, translating basic discoveries to therapeutic leads, or at a facility that requires the highest level of diagnostic testing, our award-winning tools and solutions empower scientists and clinicians to achieve reproducible and consistent
--> LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge lab facilities top of page Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. All Posts Search LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge lab facilities Jun 4, 2025 2 min read London, 4 June 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces it has entered into a license agreem
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
--> Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual Meeting top of page Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. All Posts Search Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual Meeting May 24, 2024 2 min read Updated: Apr 11, 2025 London, 24 May 2024 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company about to start clinical trial
LIfT Biosciences adds patents for cancer treatment | Antonin D. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Li
LIfT Biosciences Establishes Scientific Advisory Board to Accelerate Development of Neutrophil-based Cancer Therapies Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management Brexit Sport Premier League Football Formula 1 Rugby Cricket Go … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets open in 6h 32m UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets open in 6h 32m FTSE 100 10,529.89 +68.26 +0.65% GBP/USD 1.3192 -0.0006 -0.04% GBP/EUR 1.1604 +0.0007 +0.06% FTSE 250 23,161.41 +59.89 +0.26% AIM 771.92 -5.45 -0.70% GOLD FUTURES 4,037.20 -10.40 … NSCC and cervical cancer. The consortium led by LIfT is funded by a €12 million grant awarded by Ireland's Disruptive Technologies Innovation Fund (DTIF). The Company has also successfully completed a Scientific Advice meeting with the Irish regulatory agency, HPRA. The agency's feedback allows LIfT to finalise its overall manufacturing strategy and design of its clinical study to be conducted in Ireland. Story continues "The participation from such an esteemed group of exper … ed immune checkpoint inhibitor. For this work, he was co-awarded the 2018 Nobel Prize in Physiology or Medicine. Dr. Allison is Regental Professor and Chair of the Department of Immunology, the Olga Keith Wiess Distinguished University Chair for Cancer Research, Executive Director of the Immunotherapy Platform, and Director of the James P. Allison Institute at The University of Texas MD Anderson Cancer Center. Dr. Allison's current research focuses on next-generation immune c … ancers. Her work has been recognised with awards including the William B. Coley Award in Tumor Immunology and the Emil Frei III Award for Excellence in Translational Research. Dr. Sharma is Associate Vice President of Immunobiology and Professor of Genitourinary Medical Oncology and Immunology, and Director of Scientific Programmes for the James
LIFT BioSciences Publishes Review Article in Frontiers in Immunology | Samuel Florence posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or s … treatment that initially worked? An international research team, led by Israel Prize laureate Prof. Yosef Yarden at the Weizmann Institute of Science in collaboration with the National Cancer Institute (NCI) in Bethesda, Maryland has uncovered a key mechanism behind this resistance, and found that a combination of existing drugs may help overcome it. In a new study published in EMBO Molecular Medicine, the scientists discovered that a gene alteration found in roughly half of … eport this post Professor Livnat Jerby receives the Pershing Square Sohn Cancer Prize. Her lab recently discovered that metabolite sensing can be used to engineer spatially targeted immune cells and identified RNA-based interventions to counter immune evasion. Now, with incredible support from the Pershing Square Sohn Cancer Research Alliance (PSSCRA), they will build systems to read and write the code of bioactive molecule sensing — designing new proteins and circuits for pr
LifeSpan Vision Ventures Invests in LifT BioSciences | Frank Schueler LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement ,
LIfT BioSciences gets a double boost Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Sectors Browse by sector Approaches Anti
LIfT BioSciences - BIO International Convention 2026 Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! June 7-10 | Philadelphia Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance FAQs International Visitors Why Attend Visa Invitation Letter Request Tips for International Visitors Share On Social Media For Press Media Resource Center Media Registration Engaging with the Media Request Media List Press Releases Stay in Touch Contact Us Join our mailin … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung
I am proud to share that LIfT... - LIfT BioSciences Facebook Log In LIfT BioSciences's Post LIfT BioSciences July 30, 2025 · Shared with Public I am proud to share that LIfT BioSciences has been awarded €12 million from Ireland’s Disruptive Technologies Innovation Fund (DTIF) - the largest grant in the fund’s history. This significant funding will support the advancement of our first-in-human clinical trial of our immune-modulatory alpha neutrophil immunotherapy, marking a pivotal moment as we work to achieve our mission of overcoming treatment resistance in solid tumours. What sets IMANs
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Bo Rode Hansen - BIO International Convention 2026 Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW June 22-25 | San Diego Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance FA … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung
Cell 2026 Explore our brands Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. Events In-Person & Online Events Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities. Advanced Analytical Strategies for NextGen Antibodies 17 Sep 2026 | BST (UTC+1) Cell 2026 12 - 13 Nov 2026 | London, UK NextGen Biomed 2027 18 - 19 Mar 2027 | London, UK … : Enabling Integrity and Efficiency On-demand webinar presented by Senior Field Application Scientists, Suzy Brown and George Prout LifeScienceXchange Contact Our Brands Explore our brands Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. Oxford Global Precision Medicine Discovery & Development NextGen Biomed Contact … s Programme Details Key Event Highlights An unmissable journey awaits you: from award winning speakers and insightful workshops to an exclusive gala dinner. Discover the moments that will transform your Cell experience. See All Highlights NextGen Biomed 2025 Programme Highlights Explore dynamic panels, engaging roundtables, and hands-on workshops designed to drive innovation and foster collaboration, including: Proteins, Antibodies & ADCs Panel Discussion: What Is T … tform to share your business plans. For further information and to get started, submit the application form below. Learn More Featured Speakers for Cell 2026 Agnieszka Jozwik Senior Research Scientist, Functional Genomics, AstraZeneca Ahmed Abdulgawad Haematology Consultant, Cellular Therapy and Early Phase Trials, NHS Alison Caldwell CMC Regulatory Affairs Manager, Resolution Therapeutics Amelia Lane Director of Preclinical Development, MeiraGTx Amy Sanders Research Scientis
Presenters at the 23rd BEF Forum SachsForum SachsForum EVENTS: Upcoming Events > 1st EHIS Forum 26th BEF Forum 10th NIF Forum Recent Events > 2nd OCIF > POST 2nd OCIF Participants > Attendees Investors Presenters Sponsors Supporters 19th ELSF > POST 19th ELSF Participants > Attendees Investors Presenters Exhibitors Sponsors Supporters 1st ENIF > POST 1st ENIF Participants > Attendees Investors Presenters Sponsors Supporters 9th NIF > POST 9th NIF Participants > Attendees Investors Presenters Sponsors Supporters 11th OIF > POST 11th OIF Participant … rticipation from new investors, Industrifonden, Innovestor’s Life Science Fund and P53 Invest. The proceeds will enable Teitur to progress its lead drug candidate, TT-P34 into clinical development, including a Phase 1b clinical study in neurodegenerative diseases. www.teiturtrophics.com/ Vaccentis AG Vaccentis AG is a Zurich-based company focused on the biotech and pharmaceutical sector. All research, production and sales activities of the are carried out by two highly … -of-concept clinical trial with the first product candidate ATL-105 for inhaled application in respiratory diseases. AATec was founded by a seasoned interdisciplinary team with long-standing experience in clinical research, biopharmaceutical development and product industrialization. www.aatec-medical.com Akribion Genomics AG Akribion Genomics develops a revolutionary, genetically-programmable and new therapy class for oncology, using novel nucleases, causing programmable cel … the redosing potential of SVec, but will also validate the technology for wider application. We would welcome the opportunity to introduce you to the novel gene therapy platform and to tell you more about our fundraising plans. www.amarnatherapeutics.com Amyl Therapeutics Amyl therapeutics develops a breakthrough platform of fusion proteins for the treatment of amyloid mediated diseases: amyloidosis, neurodegenerative diseases and others. ​ www.amyltx.com/ Atamyo Therap … he market by end 2027 - early 2028 thanks to potential Orphan Drug Designation (application ongoing). To date, no specific or effective treatment approaches are available during the first 72 hours of onset. bioxodes.com/ CellProthera SAS CellProthera is a clinical-stage biotech developing innovative stem cell therapies. Preliminary data from its
Instagram Instagram Log In Sign Up Close Never miss a post from vkachanov Sign up for Instagram to stay in the loop. Sign up Log in vkachanov • Follow More options vkachanov 42w Very proud of my friend Alex Blyth for his groundbreaking work fighting cancer as a CEO of Lift BioSciences. Unfortunately, Alex and I both lost our moms to cancer and we quickly became friends back in 2018 (having met in a tennis club at Wimbledon). LiFT’s work on super donor immune cells was recently highlighted in a Financial Times article (where you can find more details, including a scientific presentation). Load
What's On at Cell? Explore our brands Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. Events In-Person & Online Events Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities. Advanced Analytical Strategies for NextGen Antibodies 17 Sep 2026 | BST (UTC+1) Cell 2026 12 - 13 Nov 2026 | London, UK NextGen Biomed 2027 18 - 19 Mar 2027 | L … : Enabling Integrity and Efficiency On-demand webinar presented by Senior Field Application Scientists, Suzy Brown and George Prout LifeScienceXchange Contact Our Brands Explore our brands Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. Oxford Global Precision Medicine Discovery & Development NextGen Biomed Contact … Research Director, Bioarchitech 180 papers. He was awarded the Leonidas Zervas Award of the European Peptide Society in 2012 and the Max Bergmann Medal by the Max-Bergmann-Kreis in 2022. His research covers topics at the interface between synthetic chemistry, biology, biophysics, medicinal chemistry, and nanobioscience. He currently serves as president of the European Peptide Society."> Knud Jørgen Jensen Professor, Copenhagen University Kuda Muchandibaya Lecturer for Supply … n academia and industry. He has won numerous awards, the latest being the Bader Prize by The Royal Society of Chemistry in 2023 and Fellow of the Royal Society of Edinburgh in 2024. Vendrell currently co-heads the IRR Chemistry Hub at the College of Medicine in Edinburgh as one of the first global hubs for collaborative non-siloed research to catalyse innovation in medical sciences and accelerate translational outputs. Group website: www.dynafluors.co.uk"> Marc Vendrell Escob … tise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange
Attendee Stories - 11th CAR-TCR Summit 2026 Skip to content The Industry's Leading, Deeply Technical Flagship Cell Therapy Forum September 15-17 2026 I Boston, MA About About Event Poster Session Blogs Attendee Stories FAQs Events in the Series Hanson Wade Products What’s On? Full Event Guide Speakers Agenda Pre-Conference Day Day One Day Two Why Partner Why Partner Partners Media Partners Take Part Pricing & Registration Venue & Accommodation Contact Us Full Event Guide Register About About Event Poster Session Blogs Attendee Stories FAQs Events in the Series Hanson Wade Produ
Collaboration Deals in Biotechnology 2020-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscriptions Expert Network FA … The Jackson Laboratory The Medical Research Infrastructure and Health Services Fund of the Tel Aviv Medical Center The Native Antigen Company The New York Stem Cell Foundation The Parker Institute For Cancer Immunotherapy Theragen Theragent TheraPanacea Theriva Biologics Thermo Fisher Scientific ThinkCyte ThirdEye Tianjin CanSino Biotechnology Tianjin University Tiba Biotech TiumBio Tivic Health Systems T Med TMG - Tropical Melhoramento e Genética Today TCI Tolo Biotech Tome … rvice CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Option Promotion Research Royalty financing Settlement Spin out Sub license Supply Termination Warrant Every deal record is fully categorized and includes the following data, where available: Industry sector Therapy areas Technology type Deal components Financial terms Stage of development Exclusivity Asset type Geographic focus Excluded g … nology Related Reports Biotechnology Market Report by Product Type, Technology, Application, and Region 2026-2034  Report 138 Pages April 2026 Global From €3609 EUR $3,999 USD £3,129 GBP Biotechnology Market in the US 2025-2029  Report 170 Pages January 2025 United States From €2256 EUR $2,500 USD £1,956 GBP North America Biotechnology Market Report by Product Type, Technology, Application, Countries and Company Analysis 2025-2033  Report 200 Pages Sep … on Deals in Biotechnology 2020-2026 close close ASK A QUESTION RESERVE MY PLACE Submit the form to confirm your enrolment and receive payment instructions. An error occurred while sending the message. Should this issue persist, email us at [email protected] * Required Information Name * Mr Mrs Dr Miss Ms Prof { }..." data-val-regex-patt
LIfT BioSciences announces grant of €12 million from Ireland’s Disruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy | Stephen Geary LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . … news from the latest round of #DTIF awards (Disruptive Technologies Innovation Fund, including a €12 million grant to consortium led by #Galway & UK based LIfT BioSciences to support their first‑in‑human clinical trial of IMAN cell therapy, a groundbreaking immuno‑modulatory alpha‑neutrophil platform targeting solid tumours. Consortium partners include University of Galway and Hooke Bio Ltd. Trials are expected to start in late 2026. https://lnkd.in/efd6P28r Department o … nterprise, Tourism and Employment Enterprise Ireland LIfT BioSciences announces grant of €12 million from Ireland’s Disruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy biospace.com 5 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in More Relevant Posts Liliang Jin 8mo Report this post Proud to support innovative clinical research presented at #ESMO2025 ! 🔬 We’re excited to see the poster pres … uptake with low healthy organ exposure. The work also received the Marie Curie Award at EANM25. ☢️ Pentixapharm AG : Multiple presentations on [68Ga] in Primary Aldosteronism, including comparisons against adrenal venous sampling. ☢️ Ariceum Therapeutics : Oral presentation OP-658 on 225-Ac-SSO110 for ES-SCLC and MCC highlighted program advancement and supportive PK versus legacy constructs. ☢️ C-Ray Therapeutics : First clinical results for 225Ac-PSMA-CY313 in heavily pretr
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
Minaris and LIfT BioSciences collaborate in cell therapy development - European Biotechnology Magazine ADVERTISEMENT Stay up to date every week with the european biotechnology newsletter. ✕ Instagram This field is for validation purposes and should be left unchanged. Email (Required) This field is hidden when viewing the form EBcom NL confirm list This field is hidden when viewing the form Consent I agree to the privacy policy. Stay up to date every week with the european biotechnology newsletter. Log in here to read the desired article. Facebook This field is for validation purposes an
New collaboration for cell therapy in cancer treatment | LIFT BioSciences posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you a … ,192 followers 8mo Edited Report this post In a new study funded by an AB Nexus grant, CU Cancer Center members Dan LaBarbera , PhD, of University of Colorado Anschutz , and Karolin Luger , PhD, of University of Colorado Boulder , are looking to see if quantum computing can help researchers identify promising new treatments for colorectal cancer. “We’re trying to develop next-generation precision oncology drugs that will be more effective but also synergize with standard of c … very into the tumour while protecting healthy tissue. Supported by a $3 million grant from the U.S. Department of Defence, it represents tangible progress in paediatric cancer treatment. CRYOPDP ensures this precision through compliant, temperature-controlled transport for radiotherapeutics and clinical research materials worldwide. Read the full story about the REYOBIQ™ clinical trial: https://lnkd.in/dfCQ7z_2 . #HealthcareLogistics #LifeSciences #ClinicalTrials #AdvancedThe … YOPDP Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer - intelligence360 https://www.intelligence360.news 1 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in PDRadiopharma Inc. 324 followers 8mo Edited Report this post PDRファーマは、日本における承認臨床試験の一環として、進行前立腺がんを対象とした64Cu-PSMA-I&Tの開発を開始しました。これと並行して、その治療ペアである177Lu-PSMA-I&Tの臨床試験開始も計画しています。 Curiu
VerImmune Inc (Maryland) - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 VerImmune Inc (Maryland) Startups | Private Company | 2020 | Maryland, United States | 10-50 | www.verimmune.com Startups | Private Company | 2020 | Maryland, United States | 10-50 | www.verimmune.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Related 100 Clinical Results associated with VerImmune Inc (Maryland) Login to view more data 0 Patents (Me … rial breaches” were discovered days later, according to an SEC filing . The new deadline to complete the merger is Oct. 4. — Max Gelman Cell Therapy Immunotherapy Phase 3 License out/in Phase 2 23 Sep 2024 · www.prnewswire.com VerImmune Completes $4.5 Million First Closing of Pre-Series A Financing, Strengthens Board with Two Accomplished Biotechnology Executives BETHESDA, Md. and SINGAPORE, Sept. 23, 2024 /PRNewswire/ -- VerImmune Inc., ("VerImmune"), a venture-backed biotec … uring these innovations reach the patients who need them most. As an open-ended fund, Beiley provides not only financial backing but also access to extensive networks, enabling emerging biotech entrepreneurs to build and scale their ventures. Through strategic investments and market access support, Beiley is committed to fostering a collaborative ecosystem that drives entrepreneurial success, fuels the growth of life sciences innovation, and accelerates the delivery of transf … . About Proxima Ventures Proxima Ventures is a highly respected venture capital fund specializing in innovative and disruptive medical and biotechnology investments. With a focus on supporting companies with exceptional growth potential, Proxima is led by a seasoned team with a proven track record in life sciences. The team combines deep global expertise, extensive industry experience, and a vast network of connections. Proxima invests in companies from the angel to growth st … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view ful
Mark Exley | Advanced Therapies UK Toggle navigation Advanced Therapies UK 2027 9 - 10 March ExCel, London home our story Conference Clinicans Hub speakers agenda sponsors & exhibitors sponsor/exhibit 2026 Post-Event Report Start-Up Application Poster Application Download Prospectus Sales Catalogue register now- offer ends 26 june contact us Accommodation venue Mark Exley | CSO LIfT Biosciences Mark Exley, Ph.D., is LIfT’s Chief Scientific Officer and Visiting Professor at Imperial College. He was Harvard Faculty for about 20 years and has over 40 years’ Immunology expertise, particularly … from the Institute of Cancer Research in London and completed his post-doctoral fellowship at the Dana Farber Cancer Institute, Boston. Appearances: Day 2: 10th March 2027 @ 13:00 IMANs:Neutrophil based cell therapy for cancer and beyond Mark Exley, CSO, LIfT Biosciences × Mark Exley / IMANs:Neutrophil based cell therapy for cancer and beyond Mark Exley, CSO, LIfT Biosciences Mark Exley, Ph.D., is LIfT’s Chief Scientific Officer and Visiting Professor at Imperial Colleg
--> N-LIfT cell therapy shows complete and superior cell killing in solid tumour organoid top of page Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. All Posts Search N-LIfT cell therapy shows complete and superior cell killing in solid tumour organoid Mar 6, 2022 4 min read Updated: Apr 11, 2025 London, 6th March 2022 – LIfT BioSciences,a biotech bringing to market a first-in-class allogeneic innate cell therapy, today announces that N-LIfT, its Neutrophil-based Leukocyte Infusion Th
> Capricor to begin filing DMD drug with FDA next month; Surrozen’s $10M milestone: Plus, news about Adaptimmune, Roche, LifT BioSciences, VerImmune, and Revance Therapeutics: Capricor Therapeutics to file Duchenne cardiomyopathy treatment with the FDA: The San Diego-based biotech in October plans to start work on a BLA filing for its allogeneic cell therapy, deramiocel, aiming for full approval. The submission will include cardiac data from the company’s Phase 2 HOPE-2 trial and open-label extension. Deramiocel is also under investigation in the Phase 3 HOPE-3 trial. The company’s shares $CAP … erial breaches” were discovered days later, according to an SEC filing. The new deadline to complete the merger is Oct. 4. — Max Gelman #lucidquest #genetherapy #celltherapy"> > Capricor to begin filing DMD drug with FDA next month; Surrozen’s $10M milestone: Plus, news about Adaptimmune, Roche, LifT BioSciences, VerImmune, and Revance Therapeutics: Capricor Therapeutics to file Duchenne cardiomyopathy treatment with the FDA: The San Diego-based biotech in October plans to st … erial breaches” were discovered days later, according to an SEC filing. The new deadline to complete the merger is Oct. 4. — Max Gelman #lucidquest #genetherapy #celltherapy"> > Capricor to begin filing DMD drug with FDA next month; Surrozen’s $10M milestone: Plus, news about Adaptimmune, Roche, LifT BioSciences, VerImmune, and Revance Therapeutics: Capricor Therapeutics to file Duchenne cardiomyopathy treatment with the FDA: The San Diego-based biotech in October plans to st … erial breaches” were discovered days later, according to an SEC filing. The new deadline to complete the merger is Oct. 4. — Max Gelman #lucidquest #genetherapy #celltherapy"> Capricor to begin filing DMD drug with FDA next month; Surrozen’s $10M milestone | Dr. Timos Papagatsias LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professio … erial breaches” were discovered days later, according to an SEC filing. The new deadline to complete the merger is Oct. 4. — Max Gelman #lucidquest #genetherapy #celltherapy Capricor to begin filing DMD drug with FDA next month; Surrozen’s $10M milestone endpts.com Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in 27,7
--> Company | Lift Biosciences Cancer Cell Therapy top of page Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. Company Pipeline Our novel pipeline is purposefully designed to advance LIFT BioSciences’ platform of delivering transformational, allogeneic neutrophil based therapies that meaningfully improve patient outcomes. Spanning unmodified IMANs and next-generation Engineered IMANs, our programs reflect a strategic, risk-balanced approach that validates our technology across mu
Lift Biosciences - 11th Innate Killer Summit Skip to content This event has run. Thank you to our speakers, sponsors, and delegates who joined us for the 2026 summit. Returning March 2027 About About Event FAQs Interview with Nina Horowitz Hanson Wade Products What’s On? Full Event Guide Speakers Why Partner Why Partner Partners Media Partners Take Part Register Interest Contact Us Previous Event Guide Register Interest About About Event FAQs Interview with Nina Horowitz Hanson Wade Products What’s On? Full Event Guide Speakers Why Partner Why Partner Partners Media Partners Take P
LIfT Biosciences partners with University of Galway and Hooke Bio Ltd. | LIFT BioSciences posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join o … of this process while adhering to strict QA/QC regulations in this informative Application Note from Logos Biosystems. Here, the LUNA-FX7™ Automated Cell Counter was used to demonstrate cell health and viability at each critical stage of CAR-T cell therapy production. #celltherapy #medicalresearch #researchanddevelopment #biotechnology 14 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in MVRIX Co., Ltd 134 followers 8mo Report this post
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
--> Innate Immunity Cancer Cure Biotech | LIfT BioSciences | United Kingdom top of page Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. Re-arming the innate immune system against solid tumours Immunomodulatory Alpha Neutrophils (IMANs) are first-in-class, off-the-shelf neutrophil-lineage cell therapies designed to directly kill tu … 40th Society for Immunotherapy of Cancer Nov 6, 2025 LIfT BioSciences announces grant of €12 million from Ireland’sDisruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy Jul 29, 2025 1 2 3 4 5 View All News Learn More Company UK Office LIFT BioSciences London BioScience Innovation Centre 2 Royal College Street London NW1 0NH United Kingdom Company Reg: 09277638 Ireland Office Eolaíocht Bhitheach LIFT Teoranta P&
LIfT BioSciences Careers, Perks + Culture | Built In Companies Jobs Articles Can't find your company? Create a company profile. View All Jobs Join Log In For Employers Companies LIfT BioSciences Teams LIfT BioSciences Save Saved London 50 Total Employees Year Founded: 2016 View Website Overview Jobs Offices Is This Your Company? Claim Profile Healthtech Biotech LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s
Lift Biosciences - 9th CAR-TCR Summit Europe 2026 Skip to content This event has run. Thank you to our speakers, sponsors, and delegates who joined us for the 2026 summit. Ran February, 2026 About About Event Hanson Wade Products What’s On? 2026 Full Event Guide 2026 Speakers 2026 Agenda Strategic Bootcamp Day Day One Day Two Why Partner Why Partner 2026 Partners 2026 Media Partners Partnership Prospectus Take Part Register Interest Contact Us 2026 Event Guide Register Interest About About Event Hanson Wade Products What’s On? 2026 Full Event Guide 2026 Speakers 2026 Agenda Strateg
LIfT BioSciences partners with Bayer for biotech innovation | LIFT BioSciences posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in,
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
--> LIfT BioSciences announces grant of €12 million from Ireland’sDisruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy top of page Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. All Posts Search LIfT BioSciences announces grant of €12 million from Ireland’sDisruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy Jul 29, 2025 4 min read Galway, London, 29 July 2025– LIfT BioScience … biotech and the global leader in neutrophil immunotherapies, today announces a grant of €12 million has been awarded from Ireland’s Disruptive Technologies Innovation Fund (DTIF) to advance its Immuno-Modulatory Alpha Neutrophils (IMANs), designed to overcome treatment resistance in solid tumours, through first-in-human clinical trials expected to start in Q4 2026. The €12 million grant, the largest grant awarded by the DTIF to date, was awarded to a consortium LIfT formed w … s platform designed to enhance therapy response rates, as part of the Company’s grant application process. The funding will be used to conduct an investigator initiated clinical trial designed to test the feasibility and safety of IMAN therapy administered to patients with metastatic cervical cancer or head and neck cancer who have exhausted all standard treatment options, including checkpoint inhibitors. Alex Blyth, Chief Executive Officer of LIfT Biosciences, said: “The gra … and accelerating the path to delivering IMANs to patients. The majority of this grant will support CMC manufacturing and the clinical trial itself, positioning LIfT at the forefront of next-generation cancer immunotherapies.” Commenting on the award, Peter Burke, Minister for Enterprise, Tourism and Employment , said that “The Government established the Disruptive Technologies Innovation Fund to invest in technologies that demonstrate true innovation and with the potential to … the potential to address critical national and societal challenges. We want to fund projects that will make a real difference to people’s lives. The N-LIfT project has come through a rigorous evaluation process and the level of funding awarded reflects its potential to be a game-changer in cancer therapy. I’m excited to see the impact it will de
Jobs Companies Career Hub CV Analysis Industry Insights Career Guides Roles Library For employers Sign in Find my fit Jobs Companies Career Hub CV Analysis Industry Insights Career Guides Roles Library For employers Sign in Find my fit LIFT BioSciences Generated by Meeveem AI "Pioneering neutrophil cell therapies to kill solid tumours and restore immune response" London • 11 - 50 Employees • Biotechnology Claim this profile for free Connect About About LIFT BioSciences LIfT BioSciences develops first-in-class Immunomodulatory Alpha Neutrophil (IMAN) cell therapies for hard-to-treat s
--> LIfT BioSciences and Minaris Regenerative Medicine Enter into a Manufacturing Partnership top of page Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. All Posts Search LIfT BioSciences and Minaris Regenerative Medicine Enter into a Manufacturing Partnership Feb 16, 2023 3 min read Updated: Apr 11, 2025 GMP N-LIfT being produced for forthcoming clinical trials LONDON, UK and MUNICH, Germany – February 16th, 2023. LIfT BioSciences, a pioneering pre-clinical stage company moving into f
--> LIfT BioSciences Expands U.S. Footprint with New Facility at Portal Innovations, Houston Helix Park top of page Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. All Posts Search LIfT BioSciences Expands U.S. Footprint with New Facility at Portal Innovations, Houston Helix Park Jun 25, 2025 2 min read London, 25 June 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces it has entered into an
--> LIfT BioSciences secures its largest financing to date with a further £5m top of page Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. All Posts Search LIfT BioSciences secures its largest financing to date with a further £5m Jan 21, 2022 3 min read Updated: Apr 11, 2025 London, 21st January 2022 – Biotech LIfT BioSciences today announced its largest financing round to date with a further £5m investment into the company in its mission to develop the first curative and affordable ce … er develop its manufacturing technology to cost-effectively produce N-LIfT, and fund pre-clinical in-vivo work. LIfT BioSciences is looking to demonstrate in-vivo superiority over standard of care in Pancreatic Ductal Adenocarcinoma (PDAC), Hepatocellular Carcinoma (HCC) and other solid tumour types under investigation. Fig 1. How N-LIfT is produced and envisaged to be administered to patients in the future LIfT is currently in discussions with major pharmaceutical companies … ning research on the root causes of aging into therapies and services for human application. Investments include Cellvie, Underdog, Revel Pharmaceuticals, Elastrin Therapeutics and others. For more information, please visit: www.kizoo.com and www.forever-healthy.org About Jonathan Milner: Jonathan Milner, Founder of Abcam plc, is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable in
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
LIfT BioSciences IMAN therapy shows killing of cancer tumoroids Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Sectors Brows
LIfT BioSciences - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events DDII Events Series Other Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies Microbiome Drug Discovery Cell Science … es receives €12m to support solid tumour trials LIfT BioSciences has received a grant of €12 million from Ireland’s Disruptive Technologies Innovation Fund (DTIF) to advance its Immuno-Modulatory Alpha Neutrophils (IMANs), designed to overcome treatment resistance in solid tumours, through first-in-human clinical trials expected to start in Q4 2026. The €12 million grant, the largest… Read More 4 August 2025 #Business & Investment #News Resources Webinars Webinar &
LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer | STEM Times of Connecticut Searching… AGP Picks War Horrors Come Home to Russia Peter Thiel’s Secret Society, Exposed. “Build-a-Cult” Supreme Court Restricts Americans’ Ability to sue Pesticide Makers Dreamy Paris Rooftops Become a Heat-Trapping Nightmare Betting on Boots-on-the-Ground Journalism Trust in Media 2026: Which News Sources Americans Use and Trust Will Surrendering to Iran Relieve Trump’s Gas Pains? Supreme Court Rejects Hawaii gun Restrictions Snap Cuts Leave 700,000 Kids Hungry in US The Future of News Could Dep … mp; STEM Times of Connecticut. All Rights Reserved. About Press Release Archive Submit Press Release Terms & Conditions Copyright/DMCA Policy Privacy Policy Contact Cookie Settings / Manage Cookie Preferences dialog#clickOutside"> dialog#close" class="absolute top-5 right-5 p-0 bg-transparent border-none cursor-pointer" aria-label="Close"> Share this page: dialog#copy" class="cursor-pointer bg-transparent border-none p-0" aria-label="Copy link"> dialog#print" class="curso … ear-black text-white text-base px-5 py-2.5 rounded-lg border-0 cursor-pointer" >Apply filters advanced-search#resetFilters" class="bg-white text-near-black text-base px-5 py-2.5 rounded-lg border border-ash-grey cursor-pointer" >Reset alert-dialog#close" type="button" class="absolute top-4 right-4 cursor-pointer p-1 z-10" aria-label="Close"> Sign up for: STEM Times of Connecticut The daily local news briefing you can trust. Every day. Subscribe now. alert-dialog#submit" metho … alert. Oops! It looks like something went wrong. Please try again. alert-dialog#submit" method="POST" action="/alerts" class="flex flex-col gap-[10px]"> Email Address Sign up for free By signing up, you agree to our Terms & Conditions. You are Unsubscribed! You are no longer receiving the STEM Times of Connecticut daily news alert. Already unsubscribed You are no longer receiving the STEM Times of Connecticut daily news alert. Oops! Try clicking the Unsubscribe link in th
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Alex Blyth: Founder and CEO of LifT BioSciences - BioBoss | iHeart Your Library Podcasts News All Episodes Alex Blyth: Founder and CEO of LifT BioSciences June 18, 2022 • 36 mins BioBoss host John Simboli speaks with Alex Blyth, founder and CEO of LifT BioSciences. Listen Watch Share Mark as Played All Episodes © 2026 iHeartMedia, Inc. Help Privacy Policy Your Privacy Choices Terms of Use
BioBoss - New BioBoss podcast... Facebook Log In BioBoss's Post BioBoss June 21, 2022 · Shared with Public New BioBoss podcast https://bioboss.news/AlexBlyth featuring Alex Blyth, founder and CEO of LifT Biosciences. Hear Alex speak with BioBoss host John Simboli about leadership in biopharma and how LifT Biosciences is committed to developing the world's first 'off-the-shelf' cell therapy to destroy all solid tumors, irrespective of strain or mutation. #leadeship , #CEO , #biotech , #biopharma , #openscience , #innovation , #BioBoss , #therapeutics ,, #celltherapy , #cance
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
--> LIfT BioSciences raises £10m in first close of Series A to advance first-in-class allogeneic innate cell therapy top of page Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. All Posts Search LIfT BioSciences raises £10m in first close of Series A to advance first-in-class allogeneic innate cell therapy Sep 24, 2024 3 min read Updated: Apr 11, 2025 Proceeds will be used to advance the Company’s IMANs into clinical trials Raise underpins strong pre-clinical data demonstrating dual mec … ejuvenate patient’s immune response. We are also excited by the potential wider application this novel immuno-modulating therapy could have in the future”. About LIfT BioSciences LIfT Biosciences is a UK & Ireland biotech that is bringing to market a first-in-class alpha neutrophil cell therapy that overcomes treatment resistance in solid tumours. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest
Lift BioSciences–SEVERAL: investment, 202409 financing round Series A first closing £10m - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Roche and Nurix: up to $2.3b Agreement for BTK Degrader AMD Commits up to £2b to Ac … to Biosciences and DaltonTx: AI-Driven Collaboration » More News! » Submit your News! Upcoming Events UBS Life Sciences Conference 2026 London Metabolomics 2026 Buenos Aires BIO 2026 San Diego (BIO International Convention) TD Cowen’s Tools/Dx Revolution Conference 2026 Dana Point Truist Securities Healthcare Disruptors & Digital Health Conference 2026 New York LSI Asia ’26 Emerging MedTech Summit 2026 Singapore Longevity Summit Dublin 2026 European Spatial Comput … f America Global Healthcare Conference London 2026 » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Fujifilm Biotechnologies Appoints Christiane Bardroff as CBO Camil … n Bulling Joins ProBioGen as Chief Operating Officer » More News! » Submit your News! Financings & Acquisitions Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Upfront plus Earn-outs Lilly to Acquire LimmaTech Biologics for up to $780m in Cash InSphero Acquires PhenoVista Biosciences to Expand in US Lauxera Capita … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m Metis TechBio: $270m IPO at Hong Kong Stock Exchange NanoStruct Closes €2.6m Seed Round Led by HTGF et al. Roche to Acquire PathAI for up to $1.05b » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agree
LIfT BioSciences Ltd. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 05 Mar 2026 LIfT BioSciences Ltd. Startups | Holding Company | 2016 | United Kingdom | 10-50 | www.liftbiosciences.com Startups | Holding Company | 2016 | United Kingdom | 10-50 | www.liftbiosciences.com Last update 05 Mar 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Neoplasms Digestive System Disorders Respiratory Diseases Immune cell therapy Stem cell therapy Cell therapy Disea … ell Therapy AACR 31 Jul 2025 · www.globenewswire.com LIfT BioSciences announces grant of €12 million from Ireland’s Disruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy Galway, London, 29 July 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces a grant of €12 million has been awarded from Ireland’s Disruptive Technologies Innova … €12 million has been awarded from Ireland’s Disruptive Technologies Innovation Fund (DTIF) to advance its Immuno-Modulatory Alpha Neutrophils (IMANs), designed to overcome treatment resistance in solid tumours, through first-in-human clinical trials expected to start in Q4 2026. The €12 million grant, the largest grant awarded by the DTIF to date, was awarded to a consortium LIfT formed with the University of Galway, renowned for their expertise in cell therapy development, … s platform designed to enhance therapy response rates, as part of the Company’s grant application process. The funding will be used to conduct an investigator initiated clinical trial designed to test the feasibility and safety of IMAN therapy administered to patients with metastatic cervical cancer or head and neck cancer who have exhausted all standard treatment options, including checkpoint inhibitors. Alex Blyth, Chief Executive Officer of LIfT Biosciences, said: “The gra … and accelerating the path to delivering IMANs to patients. The majority of this grant will support CMC manufacturing and the clinical trial itself, positioning LIfT at the forefront of next-generation cancer immunotherapies.” Commenting on the award, Peter Burke, Minister for Enterprise, Tourism and Employment, said that “The Government establish
LIfT BioSciences Announces CEO Transition to Drive Next --> Accessibility: Skip TopNav LIfT BioSciences Announces CEO Transition to Drive Next Phase of Growth with Neutrophil-based Therapies January 07, 2026 05:00 ET | Source: LIfT BioSciences LIfT BioSciences Dr. Bo Rode Hansen, current Board member and Corporate Development Officer named Interim CEO Alex Blyth, Founder and CEO to step down and will continue to work with the Company at a Board level LIfT BioSciences is currently advancing its first IMAN-based product and preparing to initiate a first-in-human Phase 1 clinical trial. Th
LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge lab facilities Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management Brexit Sport Premier League Football Formula 1 Rugby Cricket Golf Tennis NFL Athletics … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets open in 7h 31m UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets open in 7h 31m FTSE 100 10,529.89 +68.26 +0.65% GBP/USD 1.3189 -0.0008 -0.06% GBP/EUR 1.1600 +0.0003 +0.03% FTSE 250 23,161.41 +59.89 +0.26% AIM 771.92 -5.45 -0.70% GOLD FUTURES 4,040.90 -6.70
--> LIfT BioSciences expands into Ireland for manufacturing & clinical operations top of page Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. All Posts Search LIfT BioSciences expands into Ireland for manufacturing & clinical operations Nov 18, 2024 4 min read Updated: Apr 11, 2025 LIfT BioSciences expands into Ireland for manufacturing & clinical operations London, 18 November 2024– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company preparing t
LIfT BioSciences - BIO International Convention 2026 Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! June 7-10 | Philadelphia Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance FAQs International Visitors Why Attend Visa Invitation Letter Request Tips for International Visitors Share On Social Media For Press Media Resource Center Media Registration Engaging with the Media Request Media List Press Releases Stay in Touch Contact Us Join our mailin … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung
LiFT Biosciences bags €12m grant to take cell therapy to clinical trials Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Pro … ials East Coast 2027 Buy Reports Newsletters CT News LIfT Biosciences bags €12m grant to advance novel cell therapy to clinical trials This funding will allow LiFT to take its immuno-modulatory alpha neutrophil (IMAN)-based therapy to Phase I clinical trials for solid tumour indications. July 30, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The company is progressing iPSC technology and genetic engineering in collaboration with pharmaceutical partners t … red €12m ($13.74m) in funding from Ireland’s Disruptive Technologies Innovation Fund (DTIF) to advance its novel IMAN cell therapy platform to clinical trials. Composed of immunomodulatory anti-tumour neutrophils, the therapy is designed to replace dysfunctional pro-tumour neutrophils, helping to “overcome treatment resistance, improve response and avoid relapse in patients with solid tumours”, explained LIfT’s CEO, Alex Blyth. Go deeper with GlobalData Reports LOA and PTSR M
--> Innate Immunity Cancer Cure Biotech | LIfT BioSciences | United Kingdom top of page Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. Re-arming the innate immune system against solid tumours Immunomodulatory Alpha Neutrophils (IMANs) are first-in-class, off-the-shelf neutrophil-lineage cell therapies designed to directly kill tu … 40th Society for Immunotherapy of Cancer Nov 6, 2025 LIfT BioSciences announces grant of €12 million from Ireland’sDisruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy Jul 29, 2025 1 2 3 4 5 View All News Learn More Company UK Office LIFT BioSciences London BioScience Innovation Centre 2 Royal College Street London NW1 0NH United Kingdom Company Reg: 09277638 Ireland Office Eolaíocht Bhitheach LIFT Teoranta P&
#appointment #celltherapy #cancer #neutrophils #oncology | LIFT BioSciences | 19 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedI
Skip to main content MedPath Trial Home Trials Products Organizations News Research Pricing Search 中 Login Data Sources: ClinicalTrials.gov EU CTR FDA EMA NMPA TGA Health Canada WHO ICTRP MedPath Trial Home Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research. Product Clinical Trials Drug Intelligence Global Approvals AI Research Pricing Resources FAQ Search Company News About Contact Legal Privacy Policy Terms of Service Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medica
--> LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer top of page Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. All Posts Search LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer Apr 7, 2025 3 min read Updated: Dec 3, 2025 Mark brings 30 years of experience in R&D spanning discovery to late-stage clinical development London, 7 April 2025 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and world leader in neutrophil imm
--> LIfT Biosciences Establishes Scientific Advisory Board to Accelerate Development of Neutrophil-based Cancer Therapies top of page Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. All Posts Search LIfT Biosciences Establishes Scientific Advisory Board to Accelerate Development of Neutrophil-based Cancer Therapies May 7 5 min read - Members include Nobel laureate James P. Allison, Padmanee Sharma, Taha Merghoub, and Kingston Mills, who are all globally renowned experts in cancer immun … NSCC and cervical cancer. The consortium led by LIfT is funded by a €12 million grant awarded by Ireland’s Disruptive Technologies Innovation Fund (DTIF). The Company has also successfully completed a Scientific Advice meeting with the Irish regulatory agency, HPRA. The agency's feedback allows LIfT to finalise its overall manufacturing strategy and design of its clinical study to be conducted in Ireland. “The participation from such an esteemed group of experts from the … ed immune checkpoint inhibitor. For this work, he was co-awarded the 2018 Nobel Prize in Physiology or Medicine. Dr. Allison is Regental Professor and Chair of the Department of Immunology, the Olga Keith Wiess Distinguished University Chair for Cancer Research, Executive Director of the Immunotherapy Platform, and Director of the James P. Allison Institute at The University of Texas MD Anderson Cancer Center. Dr. Allison’s current research focuses on next-generation immune c … ancers. Her work has been recognised with awards including the William B. Coley Award in Tumor Immunology and the Emil Frei III Award for Excellence in Translational Research. Dr. Sharma is Associate Vice President of Immunobiology and Professor of Genitourinary Medical Oncology and Immunology, and Director of Scientific Programmes for the James P. Allison Institute at The University of Texas MD Anderson Cancer Center. She holds an MD and a PhD from Pennsylvania State Univers … une-based cancer therapies and bridging fundamental immunobiology with clinical application. This work has advanced multiple immunotherapy strategies through highly collaborative efforts across leading academic, clinical and industry partners. Dr. Merghoub is Deputy Director of the Meyer Cancer Center, Margaret and Herman Sokol Professor of Oncol
Immunomodulatory Alpha Neutrophils(LIfT BioSciences) - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 27 May 2026 Immunomodulatory Alpha Neutrophils(LIfT BioSciences) Last update 27 May 2026 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Immune cell therapy Synonyms IMANs(LIfT BioSciences) Target - Action - Mechanism - Therapeutic Areas Neoplasms Immune System Diseases Nervous System Diseases + [5] Active Indication Cervical Squam
--> LIfT BioSciences appoints Dr Bo Rode Hansen and Dr Marco Gottardis to its Board of Directors top of page Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. All Posts Search LIfT BioSciences appoints Dr Bo Rode Hansen and Dr Marco Gottardis to its Board of Directors Dec 21, 2023 3 min read Updated: Apr 11, 2025 London, 21st December 2023 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company bringing to market a first-in-class allogeneic innate cell therapy,
Colophon MedWatch Sections Pharma & biotech Medtech Hearing health Regulation & Society Other RSS feeds Follow us on Editor Ulrich Quistgaard [email protected] Tel.: +45 3330 8349 Read about the editorial team Press Releases [email protected] Debate [email protected] We take responsibility for the content and are signed up to Pressenævnet Editorial guidelines Review of quotes by sources Use of AI Employee stock investments Subscription Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company. [email protected] Tel.: +45 70 77 71 25 Buy subsc
--> Dr. Bo Rode Hansen explains why he joined LIfT as a Non-Executive Director top of page Home About Company Board of Directors Team Scientific Advisory Board Pipeline Science Investors News Contact More Use tab to navigate through the menu items. All Posts Search Dr. Bo Rode Hansen explains why he joined LIfT as a Non-Executive Director Mar 5, 2024 1 min read Updated: May 15, 2024 We recently caught up with Dr. Bo Rode Hansen, a Non-Executive Director at LIfT, to find out what motivated him to join LIfT and why he thinks our platform could make a real difference for patients with cancer. Rec
Alex Blyth, LIfT BioSciences Ltd: Profile and Biography - Bloomberg Markets Skip To Content Skip to content Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Bloomberg Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world For Customers Bloomberg Anywhere Remote Login Software Updates Manage Products and